Ani Pharmaceuticals (ANIP) Capital Expenditures Growth (3y) (2013 - 2026)
Ani Pharmaceuticals (ANIP) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.47 Bn | 30.53 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.10 Bn | 20.95 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 28.56% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 37.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.26% |
| Dec 31, 2025 | -264.77% |
| Sep 30, 2025 | 132.78% |
| Jun 30, 2025 | 118.22% |
| Mar 31, 2025 | 59.26% |
| Dec 31, 2024 | -378.22% |
| Sep 30, 2024 | 112.76% |
| Jun 30, 2024 | -24.82% |
| Mar 31, 2024 | 20.52% |
| Dec 31, 2023 | -66.27% |
| Sep 30, 2023 | -47.23% |
| Jun 30, 2023 | 56.25% |
| Mar 31, 2023 | 15.14% |
| Dec 31, 2022 | 0.54% |
| Sep 30, 2022 | -54.13% |
| Jun 30, 2022 | 32.39% |
| Mar 31, 2022 | -47.76% |
| Dec 31, 2021 | -50.25% |
| Sep 30, 2021 | -46.86% |
| Jun 30, 2021 | -34.57% |